GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio View Ltd (XTAE:BIOV) » Definitions » 3-Year Sharpe Ratio

Bio View (XTAE:BIOV) 3-Year Sharpe Ratio : -0.68 (As of Jul. 19, 2025)


View and export this data going back to 2006. Start your Free Trial

What is Bio View 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-07-19), Bio View's 3-Year Sharpe Ratio is -0.68.


Competitive Comparison of Bio View's 3-Year Sharpe Ratio

For the Medical Devices subindustry, Bio View's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio View's 3-Year Sharpe Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio View's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Bio View's 3-Year Sharpe Ratio falls into.


;
;

Bio View 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.


Bio View  (XTAE:BIOV) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Bio View 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Bio View's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio View Business Description

Traded in Other Exchanges
N/A
Address
3 Pekeris Street, Rehovot, ISR, 7670203
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.

Bio View Headlines

No Headlines